Finally, combined evaluation of rs671, BMD and FRAXTM may provide a reliable index to predict hip fractures.
The novelty in this approach stems from the combined evaluation of globally calculated and locally resolved strain patterns which track the 3D damage process.
In that respect, it was agreed upon to give the economic return a higher weight within a combined evaluation of the economic and ecological site suitability.
Therefore, the incremental benefit to identify high risk patients is achieved by the combined evaluation of these two biomarkers.
Indeed, together with the preliminary data of a small cohort (Fig. S1), these data suggested that the combined evaluation of RB1, RB1CC1, and p53 might provide useful information as prognostic biomarkers.
Our present data demonstrate that the combined evaluation of RB1CC1, RB1 and p53 by conventional immunohistochemical analysis provides an accurate prediction of the long-term prognoses of breast cancer patients, which can be carried out as a routine clinical examination.
This combined evaluation of RB1CC1/RB1/p53 can provide a benefit for the clinical management of breast cancer patients, and improve upon the individual evaluations of RB1, p53 or triple-negativity [ER, PR and HER2] to predict the long-term prognosis of breast cancer patients[1], [2], [3], [6], [30], [31], [32], [33].
Combined evaluation of several immunological variables could provide added value over single ones.
Combined evaluation of CTA and rsCTP had higher overall diagnostic accuracy of significant stenosis (50% cut-off).
